Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Non-invasive diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD) remain unmet medical needs. Aim of this study is to investigate the blood levels of three hormonal systems related to obesity, insulin resistance and inflammation in patients with different stages of NAFLD, in order to identify potential diagnostic markers.
Study aim: To compare the blood levels of: a) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), b) follistatins-activins (follistatin-like (FSTL)3, activin B), c) IGF axis (insulin-like growth factor (IGF)-1, total and intact IGF binding protein (IGFBP)-3 and IGFBP-4, in 18 individuals with early stage NAFLD vs. 14 controls To explore the levels of GDF-15, total and intact, in NAFLD versus obese controls (OC) at baseline and during oral glucose tolerance tests (OGTTs)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-NAFLD | |||
| NAFLD |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Proglucagon-derived hormones | glucagon-like peptide GLP-1 (pg/ml) | baseline |
| Proglucagon-derived hormones | glucagon-like peptide GLP-2 (pg/ml) | baseline |
| Proglucagon-derived hormones | glicentin (pmol/l) | baseline |
| Proglucagon-derived hormones | oxyntomodulin (pg/ml) | baseline |
| Proglucagon-derived hormones | glucagon (pg/ml) | baseline |
| Proglucagon-derived hormones | major proglucagon fragment [MPGF]) (ng/ml) | baseline |
| Follistatins-activins | follistatin-like (FSTL)3 (ng/ml) | baseline |
| Follistatins-activins | activin B (pg/ml) | baseline |
| IGF axis | insulin-like growth factor (IGF)-1 (ng/ml) | baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Body Mass Index (BMI) | BMI is calculated as weight in kilograms divided by height in meters squared. | baseline |
| Biochemical parameters | Glucose (mg/dl) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Subjects from the Second Propaedeutic Department of Internal Medicine, Ippokration Hospital, Aristotle University of Thessaloniki, Greece
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hippokration General Hospital | Thessaloniki | 54642 | Greece |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38762719 | Derived | Boutari C, Stefanakis K, Simati S, Guatibonza-Garcia V, Valenzuela-Vallejo L, Anastasiou IA, Connelly MA, Kokkinos A, Mantzoros CS. Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity. Cardiovasc Diabetol. 2024 May 18;23(1):174. doi: 10.1186/s12933-024-02264-5. | |
| 31690932 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D065626 | Non-alcoholic Fatty Liver Disease |
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D005234 | Fatty Liver |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D007333 | Insulin Resistance |
Not provided
Not provided
Not provided
Not provided
Not provided
| IGF axis | total and intact IGF binding protein (IGFBP)-3 and IGFBP-4 (ng/ml) | baseline |
| Liver ultrasound | Estimation of echogenicity, hepatomegaly, and intra-hepatic vascular blurring (1: Intermediate, 1-2: Intermediate to Moderate, 2: Moderate, 3: Severe) | baseline |
| GDF-15 | Total and intact Growth differentiation factor 15 (pg/mL) | baseline |
| baseline |
| Biochemical parameters | serum aspartate transaminase (AST) (U/L), ALT (U/L) | baseline |
| Biochemical parameters | gamma-glutamyltransferase (GGT) (U/L) | baseline |
| Biochemical parameters | total cholesterol (mg/dl), triglycerides (mg/dl) and high density lipoprotein-cholesterol (HDL-C) (mg/dl), low density lipoprotein-cholesterol (LDL-C) (mg/dl) | baseline |
| Biochemical parameters | insulin (μU/ml) | baseline |
| Metabolomics and lipidomics analysis | Measured with nuclear magnetic resonance spectroscopy (NMR) by Labcorp (Morrisville, USA). | baseline |
| Derived |
| Polyzos SA, Perakakis N, Boutari C, Kountouras J, Ghaly W, Anastasilakis AD, Karagiannis A, Mantzoros CS. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e390-400. doi: 10.1210/clinem/dgz172. |
| D006946 |
| Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |